Modulation of vinblastine cytotoxicity by dilantin (phenytoin) or the protein phosphatase inhibitor okadaic acid involves the potentiation of anti-mitotic effects and induction of apoptosis in human tumour cells

British Journal of Cancer

Volumn 73, Issue 2, 1996, Pages 183-188

  Kawamura, K I ^a   Grabowski, D ^a   Weizer, K ^a   Bukowski, R ^a   Ganapathi, R ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Apoptosis; Okadaic acid; Phenytoin; Protein phosphatase; Vinblastine

Indexed keywords

ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; DOXORUBICIN; ESTERASE INHIBITOR; GLYCOPROTEIN P; OKADAIC ACID; PACLITAXEL; PHENYTOIN; PHOSPHOPROTEIN PHOSPHATASE; TUBULIN; VINBLASTINE;

ANAPHASE; APOPTOSIS; ARTICLE; CANCER CELL; CELL DEATH; CELL GROWTH; CONTROLLED STUDY; CULTURE MEDIUM; CYTOTOXICITY; DRUG POTENTIATION; DRUG TRANSPORT; GROWTH INHIBITION; HUMAN; HUMAN CELL; INTERPHASE; LEUKEMIA CELL; LUNG NON SMALL CELL CANCER; METAPHASE; MITOSIS; MITOSIS SPINDLE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

ANTICONVULSANTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG SYNERGISM; ETHERS, CYCLIC; HL-60 CELLS; HUMANS; LUNG NEOPLASMS; MITOSIS; MITOTIC SPINDLE APPARATUS; OKADAIC ACID; PHENYTOIN; PHOSPHOPROTEIN PHOSPHATASE; TUMOR CELLS, CULTURED; VINBLASTINE;

EID: 0030025901     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.33     Document Type: Article

References (25)

1. CHAMBERS TC, RAYMOR RL AND KUO JF. (1993). Multidrug-resistant human KB carcinoma cells are highly resistant to the protein phosphatase inhibitors okadaic acid and calyculin A. Analysis of potential mechanisms involved in toxin resistance. Int. J. Cancer, 53, 323-327.
2. COLLINS SJ. (1987). The HL-60 promyelocytic leukemia cell line: Proliferation, differentiation and cellular oncogene expression. Blood, 70, 1233-1244.
3. ENDICOTT JA AND LING V. (1989). The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu. Rev. Biochem., 58, 137-171.
4. ERIKSSON JE, BRAUTIGAN DL, VALLEE R, OLMSTED J, FUJIKI H AND GOLDMAN RD. (1992). Cytoskeletal integrity in interphase cells requires protein phosphatase activity. Proc. Natl Acad. Sci. USA, 89, 11093-11097.
5. FERNANDE A, BRAUTIGAN DL AND LAMB NJC. (1992). Protein phosphatase type 1 in mammalian cell mitosis chromosomal localization and involvement in mitotic exit. J. Cell Biol., 116, 1421-1430.
6. GANAPATHI R, HERCBERGS A, GRABOWSKI D AND FORD J. (1993). Selective enhancement of vincristine cytotoxicity in multidrug-resistant tumor cells by Dilantin (Phenytoin). Cancer Res., 53, 3262-3265.
7. GAVRIELI Y, SHERMAN Y AND BEN-SASSON SA. (1992). Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol., 119, 493-501.
8. GEORGES E, SHAROM F AND LING V. (1990). Multidrug resistance and chemosensitization: Therapeutic implications for cancer chemotherapy. Adv. Pharmacol., 21, 185-220.
9. GOTTESMAN MM AND PASTAN I. (1993). Biochemistry of multidrug reistance by the multidrug transporter. Annu. Rev. Biochem., 62, 385-427.
10. GRANT S, JARVIS WD, SWERDLOW PS, TURNER AJ, TAYLOR RS, WALLACE HJ, LIN P-S, PETTIT GR AND GEWIRTZ DA. (1992). Potentiation of the activity of 1-β-D-arabinofuranosylcytosine by the protein kinase C activator bryostatin 1 in HL-60 cells: association with enhanced fragmentation of mature DNA. Cancer Res., 52, 6270-6278.
11. GURLAND G AND GUNDERSEN GG. (1993). Protein phosphatase inhibitors induce the selective breakdown of stable microtubules in fibroblasts and epithelial cells. Proc. Natl Acad. Sci., USA, 90, 8827-8831.
12. KERR JFR, WINTERFORD CM AND HARMON BV. (1994). Apoptotis: Its significance in cancer and cancer therapy. Cancer, 73, 2013-2026.
13. LEUNG MF, SOKOLOSKI JA AND SARTORELLI AC (1992). Changes in microtubules, microtubule associated proteins, and intermediate filaments during differentiation of HL-60 leukemia cells. Cancer Res., 52, 949-954.
14. MACKINNEY AA, VYAS RS AND WALKER D. (1978). Hydantoin drugs inhibit polymerization of pure microtubular protein. J. Pharmacol. Exp. Ther., 204, 189-194.
15. MACKINNEY AA, VYAS R, MUELLER C AND GORDER CA. (1980). Comparison of potency of hydantoins in metaphase arrest and inhibition of microtubular polymerization. Mol. Pharmacol., 17, 275-278.
16. OREN M. (1994). Relationship of p53 to the control of apoptotic cell death. Semin. Cancer Biol., 5, 221-227.
17. PEEREBOOM DM, GANAPATHI R, AARON R, MCLAIN DA, BUDD GT, OLENCKI TE AND BUKOWSKI RM. (1995). Modulation of resistance to vinca alkaloids: a phase I trial of vinblastine with phenytoin. Proc. Am. Assoc. Cancer Res., 36, 246.
18. RALL TW AND SCHLEIFER LS. (1990). Drugs effective in the therapy of the epilepsies. In The Pharmacological Basis of Therapeutics, Gilman AG, Rall TW, Nies AS, Taylor P (eds). pp. 436-462, Pergamon Press: New York.
19. ROWINSKY EK AND DONEHOWER RC. (1992). Vinca alkaloids and epipodophyllotoxins. In The Chemothrapy Source book, Perry MC (ed). pp. 359-383, Williams and Wilkins: Philadelphia.
20. SMETS CA. (1994). Programmed cell death (apoptosis) and response to anti-cancer drugs. Anti Cancer Drugs, 5, 3-9.
21. VANDRE DD AND WILLS VL. (1992). Inhibition of mitosis by okadaic acid: possible involvement of a protein phosphatase 2A in the transition from metaphase to anaphase. J. Cell Sci., 101, 79-91.
22. WELLS NJ, ADDISON CM, FRY AM, GANAPATHI R AND HICKSON ID. (1994). Serine 1524 is a major site of phosphorylation on human topoisomerase IIα protein in vivo and is a substrate for casein kinase II in vitro. J. Biol. Chem., 209, 29746-29751.
23. WOLF D AND ROTTER V (1985). Major deletions in the gene encoding the p53 tumour antigen cause lack of p53 expression in HL-60 cells. Proc. Natl Acad. Sci. USA, 82, 790-794.
24. YAMASHITA K, YASUDA H, PINES J, YASUMOTO K, NISHITANI H, OHTSUBO M, HUNTER T, SUGIMURA T AND NISHIMOTO T. (1990). Okadaic acid, a potent inhibitor of type 1 and type 2A protein phosphatases, activates cdc2/H1 kinase and transiently induces a premature mitosis-like state in BHK21 cells. EMBO J., 9, 4331-4338.
25. ZHENG B, CHAMBERS TC, RAYNOR RL, MARKHAM PN, GEBEL HM, VOGLER WR AND KUO JF. (1994). Human leukemia K562 mutant (K562/OA200) selected for resistance to okadaic acid (protein phosphatase inhibitor) lacks protein kinase, exhibits multidrug resistance phenotype and exhibits drug pump P-glycoprotein. J. Biol. Chem., 269, 12332-12338.